研究人员将高风险T-ALL分类为15个子类型,使用60%的非编码基因变化,可能导致新的个性化治疗和免疫疗法。 Researchers classify high-risk T-ALL into 15 subtypes using 60% non-coding genetic changes, potentially leading to new personalized treatments and immunotherapies.
来自费城儿童医院、圣裘德儿童研究医院和儿童肿瘤小组的研究人员通过研究1 300多名病人,发现在认识高风险T-线性急性淋巴性白血病(T-ALL)方面发生了重大转变。 Researchers from Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, and the Children's Oncology Group, have revealed a significant shift in understanding high-risk T-lineage acute lymphoblastic leukemia (T-ALL) by studying over 1,300 patients. 导致T-ALL癌细胞的非编码变化的大约60%的基因变化从根本上改变了对T-ALL生物学的理解。 Approximately 60% of genetic changes driving T-ALL cancer cells are non-coding changes, fundamentally altering the understanding of T-ALL biology. 这项研究使研究人员能够将T-ALL分类为15个子类型,具有独特的基因表达和基因组驱动因素,这可能导致新的个性化治疗计划和创新的免疫疗法。 The study allowed researchers to classify T-ALL into 15 subtypes with distinct gene expression and genomic drivers, which may lead to new personalized treatment plans and innovative immunotherapies.